

RESEARCH ARTICLE

# Melanoma Cell Adhesion and Migration Is Modulated by the Uronyl 2-O Sulfotransferase

Katerina Nikolovska<sup>1,2</sup>, Dorothe Spillmann<sup>3</sup>, Jörg Haier<sup>4</sup>, Andrea Ladányi<sup>5</sup>, Christian Stock<sup>2</sup>, Daniela G. Seidler<sup>1,2\*</sup>

**1** Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany, **2** Centre for Internal Medicine, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany, **3** Department of Medical Biochemistry and Microbiology, Biomedical Center, Uppsala University, Uppsala, Sweden, **4** Comprehensive Cancer Center Münster, University Hospital Münster, Münster, Germany, **5** Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary

\* [Seidler.Daniela@mh-hannover.de](mailto:Seidler.Daniela@mh-hannover.de)



**OPEN ACCESS**

**Citation:** Nikolovska K, Spillmann D, Haier J, Ladányi A, Stock C, Seidler DG (2017) Melanoma Cell Adhesion and Migration Is Modulated by the Uronyl 2-O Sulfotransferase. PLoS ONE 12(1): e0170054. doi:10.1371/journal.pone.0170054

**Editor:** Nikos K Karamanos, University of Patras, GREECE

**Received:** August 30, 2016

**Accepted:** December 28, 2016

**Published:** January 20, 2017

**Copyright:** © 2017 Nikolovska et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was financially supported by the German Research Foundation (SE1431/3-1) to DGS, German Cancer Aid (#111262) to DGS and CS, and the German Research Foundation - GRK 1549 International Research Training Group 'Molecular and Cellular GlycoSciences' to KN.

**Competing Interests:** The authors have declared that no competing interests exist.

## Abstract

Although the vast majority of melanomas are characterized by a high metastatic potential, if detected early, melanoma can have a good prognostic outcome. However, once metastasised, the prognosis is bleak. We showed previously that uronyl-2-O sulfotransferase (*Ust*) and 2-O sulfation of chondroitin/dermatan sulfate (CS/DS) are involved in cell migration. To demonstrate an impact of 2-O sulfation in metastasis we knocked-down *Ust* in mouse melanoma cells. This significantly reduced the amount of *Ust* protein and enzyme activity. Furthermore, *in vitro* cell motility and adhesion were significantly reduced correlating with the decrease of cellular *Ust* protein. Single cell migration of B16V<sup>shUst(16)</sup> cells showed a decreased cell movement phenotype. The adhesion of B16V cells to fibronectin depended on  $\alpha 5\beta 1$  but not  $\alpha v\beta 3$  integrin. Inhibition of glycosaminoglycan sulfation or blocking fibroblast growth factor receptor (FgfR) reduced  $\alpha 5$  integrin in B16V cell lines. Interestingly, FgfR1 expression and activation was reduced in *Ust* knock-down cells. *In vivo*, pulmonary metastasis of B16V<sup>shUst</sup> cells was prevented due to a reduction of  $\alpha 5$  integrin. As a proof of concept *UST* knock-down in human melanoma cells also showed a reduction in *ITGa5* and adhesion. This is the first study showing that *Ust*, and consequently 2-O sulfation of the low affinity receptor for FgfR CS/DS, reduces *Itga5* and leads to an impaired adhesion and migration of melanoma cells.

## Introduction

A critical event in tumorigenesis of melanoma is the conversion from a primary tumor into an aggressive, metastasizing tumor. Tumor metastasis is a complex process involving its stroma, cell migration and invasion. Cell surface glycans, especially proteoglycans are involved in different stages of metastasis [1, 2]. Proteoglycans are proteins covalently modified by a linear glycosaminoglycan (GAG) chain composed of repeating disaccharide units of an amino sugar and uronic acid [3]. Physiologically, GAGs are involved in multiple cellular functions, such as

**Abbreviations:** B16V, Mouse melanoma cell line; CS/DS, chondroitin/dermatan sulfate; GAG, glycosaminoglycan; MV3, human melanoma cell line; Ust, uronyl 2-O sulfotransferase.

cell–matrix, cell–cell and ligand–receptor interactions. GAGs such as heparin/heparan sulfate (HS) or chondroitin/dermatan sulfate (CS/DS) can act as low affinity receptor for the biological activity of fibroblast growth factors (FGFs) [1, 4, 5] suggesting that CS/DS might have important regulatory functions [6–8]. CS/DS are galactosaminoglycans composed of N-acetylgalactosamine (GalNAc) and either D-glucuronic acid (D-GlcUA) or L-idoic acid (L-IdoUA). The inversion of D-GlcUA to L-IdoUA occurs on the polymer level by the chondroitin-glucuronate C5-epimerase (EC 5.1.3.19) (DS-epimerase) [7], first described as SART2, a protein of unknown function over-expressed in cancer cells [9]. The microheterogeneity of CS/DS depends on the presence of (-4GlcUA $\beta$ 1-3GalNAc $\beta$ 1-) and (-4IdoUA $\alpha$ 1-3GalNAc $\beta$ 1-) which can be differentially sulfated at C4, C6 (GalNAc) and/or C2 (D-GlcUA/L-IdoUA) by specific sulfotransferases. The minor modification at C2 is introduced by uronyl 2-O sulfotransferase (UST (no EC number) which transfers a sulfate group from 3'-phosphadenosine-5-phosphosulfate. UST is encoded by only one gene (*UST*) [10]. There is evidence that GAG structures are altered during metastasis of melanoma cells due to up-regulation of CS/DS-proteoglycans [2, 11, 12]. Notably, melanoma derived GAGs display a shift from HS and DS to CS in which CS contains high amounts of GlcUA-GalNAc(6S) ( $\Delta$ diCS-6S) and  $\Delta$ diCS-nS units [13]. Enzymatic digestion of cell surface CS/DS reduces proliferation and invasion of cancer cells [14]. The understanding of the mechanism of action of the sulfotransferases has recently progressed by the discovery that the chondroitin 4-O sulfotransferase encoded by *CHST11* is involved in metastasis of breast cancer [15] and the chondroitin 4,6-O sulfotransferase encoded by *CHST15* in Lewis lung carcinoma (LCC) [16, 17]. However, Ust (small letters, because mouse) has not been studied in this context. Interestingly, B16 melanoma cells have 1.5 times more DS compared to LCC [18] suggesting that 2-O sulfation of CS/DS might play an important role in melanoma metastasis.

Previous reports showed that CS/DS affects cell adhesion and migration [7, 19] and that the lack of L-IdoUA on the cell surface leads to an impaired directed cell migration [20]. In the central nervous system, a tissue rich in CS-proteoglycans, over-sulfated CS are involved in neuronal migration and axon regeneration [19, 21]. Recently, a reduction in *CHST11* has been reported for siRNA-mediated versican knock-down in a leiomyosarcoma smooth muscle cell line [22]. Furthermore, the lack of Ust in skin of decorin-deficient mice impairs Fgf2 and Fgf7 binding and keratinocyte differentiation [23]. The occurrence of 2-O sulfated cell surface CS/DS can tune the Fgf2-mediated effect on cell migration of CHO cells and fibroblasts [5, 23].

A critical step in migration is cell adhesion which is mainly mediated via integrins, heterodimeric cell surface receptors which mediate bidirectional signaling between cells and the extracellular matrix (ECM). During cell migration the function of  $\alpha$ 5 $\beta$ 1 integrin and  $\alpha$ v $\beta$ 3 integrin is tightly regulated [24]. The role of  $\alpha$ 5 integrin in cancer progression is controversial [25].  $\alpha$ 5 integrin also plays an important role in melanoma cell motility since its upregulation enhances migration [26, 27]. This is further supported by findings that human carcinomas frequently express high levels of  $\alpha$ 5 $\beta$ 1 integrin which had been correlated with a more aggressive carcinoma phenotype [25]. For B16F10 melanoma cells a direct correlation of the metastatic potential and increased  $\alpha$ 5 integrin function was demonstrated [28].

The aim of the present study was to demonstrate that Ust is a critical regulator of melanoma cell adhesion and motility *in vitro* and *in vivo*. Reduced expression of Ust could be linked to a significant reduction of  $\alpha$ 5 integrin mRNA and protein in mouse and human melanoma cells. Our *in vivo* data showed that B16V<sup>shUst(16)</sup> cells have a significantly reduced pulmonary metastatic potential. Therefore, we can link for the first time Ust and CS/DS 2-O sulfation with  $\alpha$ 5 integrin expression, an important factor for metastasis of melanoma cells.

## Materials and Methods

### Materials

The following primary antibodies were used: UST D-20 (Santa Cruz Biotechnology),  $\beta$ -actin, anti  $\alpha$ 5 integrin, anti  $\beta$ 1 integrin (Millipore), Alexa Fluor<sup>®</sup> 647 anti-mouse CD49e, LEAF™  $\beta$ 1,  $\alpha$ 5,  $\alpha$ v and  $\beta$ 3 integrin blocking antibodies (anti-mouse, BioLegend, California, USA) anti-rabbit-HRP secondary antibody (GE Healthcare, UK). F-actin was visualized by Alexa488-conjugated phalloidin (Invitrogen, USA). PD173074, fibronectin, mouse-Fgf2, chondroitin 6-sulfate (CS-6S) (Sigma Aldrich, Deisenhofen, Germany), chondroitin ABC lyase and heparinase mix (heparinase II/III, 4:1) (Amsbio, UK).

### Cell culture

Murine melanoma (B16V) cells [29] were grown to confluence in bicarbonate buffered RPMI 1640 (Sigma) supplemented with 10% (v/v) bovine serum (FBS) at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>. Of note, B16V cells display a black color due to their melanin. All experiments were performed at passages where cells contained melanin. Human HT168-M1, HT199 [30] and MV3 [31] melanoma cells were grown in RPMI 1640 with 10% (v/v) FBS and cultured as described before.

### Knock-down of *Ust* in melanoma cells

B16V cells were stably transfected with shRNA-*Ust*(m) plasmid as a pool of 3 target-specific lentiviral vector plasmids, each encoding 19–25 nt (plus hairpin) shRNAs designed to knock-down *Ust* gene expression (Santa Cruz), following the manufacturer's protocol. Control cells were mock transfected with shRNA plasmid-A. Cells were selected with 10  $\mu$ g/ml puromycin (Santa Cruz) for 2 weeks and further subcloned by single cell limiting-dilution. For human MV3 melanoma cells, UST siRNA and the respective scrambled siRNA were used according to the manufacturer (Santa Cruz) and the cells were analyzed 48 h after transfection.

### RNA extraction and quantitative real-time PCR

Cells were harvested using RNeasy Kit and RNA transcribed into cDNA using Omniscript RT Kit (both Qiagen, Germany) as described before [32]. cDNA corresponding to 25 ng of total RNA was used as a template. Expression levels of *Ust* (mouse and human),  $\beta$ -actin, *ubiquitin* (primer sequence: [23, 33]), *Itgb1* (mItgb1-for 5' -CAA GAG GGC TGA AGA TTA CC-3', mItgb1-rev 5' -GGC ATC ACA GTT TTA TCC A-3'), *Itgb3* (mItgb3-for 5' -TGG TGC TCA GAT GAG ACT TTG TC-3', mItgb3-rev 5' -GAC TCT GGA GCA CAA TTG TCC TT-3'), *Itga5* (mItga5-for 5' -TGC TAC CTC TCC ACA GAA AAC-3', mItga5-rev 5' -GCC AGT CTT GGT GAA CTC AG-3'), *ITGA5* (hITGA5-for 5' -TGG CCT TCG GTT TAC AGT CC-3', hITGA5-rev 5' -GGA GAG CCG AAA GGA AAC CA-3'), *FgfR1* (mFgfR1-for 5' -CAA CAA GAC AGT GGC CCT GGG-3', mFgfR1-rev 5' -CCG TGC AAT AGA TAA TGA TC-3') and *FgfR3* (mFgfR2-rev 5' -CTC CAG ATA ATC TGG GGA AG3', mFgfR3-for 5' -GGA GTT CCA CTG CAA GG-3') were monitored by real-time PCR (ABI PRISM 7500, Applied Biosystems) using MESA GREEN qPCR Kit (Eurogentec, Germany). Raw data were normalized to the geometric mean of the control genes  $\beta$ -actin and *ubiquitin*. Two or more housekeeping genes lead to much more accurate results [34].

### Western blots analysis

~1x10<sup>6</sup> melanoma cells were lysed using a lysis buffer (7 M Urea, 2 mM Thiourea, 40mM Tris-HCl, 0,001% (w/v) bromphenol blue, 1% (w/v) ASB-14). Cell lysates were cleared through a

0.2  $\mu\text{m}$  filter, 20–40  $\mu\text{g}$  of protein lysates were analyzed for Ust and  $\alpha 5$  integrin. They were visualized with enhanced chemiluminescence (Perkin-Elmer Life Sciences, USA) and monitored with Fusion-SL 4.2 MP (PeqLab, Germany). Intensities were quantified as described previously [23, 33]. Of note, immune blots of the lysates before and after filtration led to the same results. The influence of the cell surface sulfation was evaluated after 6h of cell treatment with 30 mM  $\text{NaClO}_3$  [5]. For blocking FgfR, cells were incubated for 6h with PD173074 (20 mM) inhibitor as determined based on titration curves.

### Sulfotransferase activity of B16 cell lines

Sulfotransferase reaction was carried out according to the manufacturer's instructions in a 96-well plate using the universal sulfotransferase assay (R&D). Briefly, protein lysates (25–200  $\mu\text{g}$ ) of B16V cell lines were incubated with 10 mM chondroitin 6-sulfate as substrate, PAPS (R&D), and a coupling phosphatase as control. The color was developed with a Malachite reagent for 20 min at room temperature and monitored at 620 nm with an ELISA reader. A phosphate standard curve was used to determine the activity (OD/pmol). The specific activity was determined with the following equation: Specific activity (pmol/min)/ $\mu\text{g}$  =  $S(\text{OD}/\mu\text{g}) \times \text{CF}(\text{OD}/\text{pmol}) / \text{Time}(\text{min})$ , where S is the slope of the line with the OD values of the sulfotransferase assay and CF the phosphate conversion factor (taken from the phosphate standard) [5].

### Characterization of cell surface chondroitin/dermatan sulfate and heparan sulfates

GAGs were extracted from  $\sim 2 \times 10^7$  cells and highly-sulfated cell surface CS/DS were released by  $\beta$ -elimination and purified as described previously [23]. The HexUA content was determined using an m-hydroxydiphenyl reaction. Uronic acid was hydrolyzed in 80% sulfuric acid containing tetraborate at 80°C, incubated with m-hydroxydiphenyl (Sigma Aldrich) at room temperature and measured at 540nm using heparin as standard [5].

10  $\mu\text{g}$  CS/DS were digested with 10 mU of chondroitin ABC for 2h. The unsaturated disaccharides were labeled with 5  $\mu\text{l}$  of 0.1 M 2-Aminoacridon (AMAC) in 15%  $\text{CH}_3\text{COOH}/\text{DMSO}$  solution. After 10 min incubation at RT, 1 M  $\text{NaBH}_3\text{CN}$  was added and the mixture was incubated 16 h at 37°C followed by fluorophore assisted carbohydrate electrophoresis (FACE). AMAC-labeled disaccharides were separated on 30% Borate-polyacrylamid gel [35]. HS were analyzed as described before. In order to analyze HS composition, cell pellets of B16V cell lines were prepared as described previously. After enzymatic removal of CS/DS, the heparin lyase I-, II- and III- digested GAGs were fractionated by RPIP-HPLC. The peaks were identified by co-elution with standard HS disaccharides [5].

### Proliferation of melanoma cells

$3 \times 10^4$  B16V cells/ $\text{cm}^2$  cells were seeded and cultured for 24h and starved for 16h prior to the experiment. Experiments were performed in serum-free RPMI and proliferation was determined by BrdU incorporation for 16h (Cell Proliferation ELISA, Roche).

### Cell adhesion assay

Static adhesion assays were performed with  $1 \times 10^6$  cells of the different B16V cell lines or MV3 cells in the presence of the fluorescent marker 2'7'-bis-(2 carboxyethyl)-5 carboxyfluorescein acetoxy-methyl ester (Molecular Probes, USA) dissolved in DMSO as described previously [32, 36]. Labeled cells were seeded in non- or fibronectin-coated (10  $\mu\text{g}/\text{ml}$ ) 96-well plates and

incubated for 30 to 360 min at 37°C. Cell adhesion to fibronectin was quantified after 1h with an ELISA reader (Epoch, Biotek) as previously described [32]. For further adhesion experiments cells were preincubated with i) the different LEAF™ integrin blocking antibodies (5 µg/ml) for 3h at 37°C [33], ii) 6h pre-treatment with 30(mM NaClO<sub>3</sub> or iii) enzymatic digestion of cell surface HS and CS/DS with 4 mU heparitinase II/III and/or chondroitin ABC lyase for 1h at 37°C.

### Wound scratch assay and migration on 3D collagen-rich matrices

1×10<sup>5</sup> cells/cm<sup>2</sup> of B16V cell lines were seeded in 12-well plates in RPMI medium and starved overnight. An artificial wound was generated and cells were incubated with serum-free RPMI medium (control) or RPMI supplemented with 10 ng/ml Fgf2 for 20h at 37°C. Images were captured at time points 0 and 20h, using a Zeiss Axiovert 100 microscope with AxioCam ICc1 camera. Cell migration was evaluated as described [5]. For each well 2–4 pictures were acquired (n = 3 independent experiments).

Primary C57BL/6 skin fibroblasts were cultured for 10 days in 35 mm petri dishes with 1 mM L-ascorbate-2-phosphate (Sigma) to obtain a 3D ECM [37]. Confluent B16V cell lines were detached from the culture dish with trypsin/EDTA, and B16V cell suspension in serum-free RPMI1640 was added to the 10 day old and 24h serum-starved C57BL/6 fibroblast cultures. Migration of cells was monitored, evaluated and calculated as described before [38].

### Immunofluorescence analysis

1.2×10<sup>4</sup> cells/cm<sup>2</sup> cells were seeded in 8-wells slides (Zell-Kontakt, Germany) and incubated for 24h. Cells were fixed with 4% PFA/PBS and then blocked with 3% BSA/PBS for 30 min. Cell surface α5 integrins were incubated with primary antibody Alexa Fluor® 647 anti-mouse CD49e for 1h. Actin cytoskeleton and nuclei were co-visualized with phalloidin-Alexa-488 and DAPI, respectively. Fluorescence was monitored by a confocal microscope (Zeiss AxioImager M2) with 5–10 pictures per well (n = 3 independent experiments).

### Phospho-FGFR1 cell-based phosphorylation ELISA

Mouse/Human/Rat Phospho-FGFR1/FGF Receptor 1 (Y654) Cell-Based Phosphorylation ELISA Kit was used to determine the activation state of FgfR1 according to manufacturer instructions (LifeSpan Biosciences). Briefly, 20,000 cells/well were seeded in a 96-well plate and incubated overnight. Cells were starved overnight followed by treatment with PD173074 (20 nM) for 6 h to inhibit FgfR1. Cells were fixed with 4% PFA for 20 min, washed and blocked for 1 h prior to the incubation with the first antibodies i) anti-FGFR1-Phospho-Y654, ii) anti-FGFR1 or iii) anti-GAPDH overnight at 4°C. HRP-conjugated secondary antibody was incubated for 30 min and developed with a ready to use substrate. The enzyme activity was measured at OD450 nm (Epoch, Biotek). GAPDH served as an internal positive control to normalize the values. Following the colorimetric measurement the crystal violet whole-cell staining method was used to determine cell density. After staining, the results were analyzed by normalizing the absorbance values to cell amounts. pY654-FgfR1 was normalized to FgfR1 and GAPDH. The same protocol was applied for α5 integrin and normalized to GAPDH and cell number.

### FACS analysis of cell surface α5 integrin

1 x 10<sup>6</sup> of B16V cell lines were seeded in a 6-well plate for 24 h. Cells were washed with cold PBS, scraped from the plates and aliquoted to 1 x 10<sup>6</sup> cells in 10 µl 2% FBS/PBS. To detect α5



integrin cells were incubated with Alexa Fluor<sup>®</sup> 647 anti-mouse CD49e antibody (0.5 µg/100µl) for 30 min at 4°C. After 3 x washing with cold PBS, cells were resuspended in 1 ml 2% FBS/PBS and analyzed with FACS Aria IIu. Non-stained and isotope controls were analyzed simultaneously.

## Animal experiments and B16 syngenic tumors

10 weeks old female C57BL/6 mice (Charles River, Germany) were grouped into 5 and kept for one week prior to the experiments and cared according to the standards of the German Council on Animal Care and Institutional Animal Care and Use Committee. Animals were housed in the animal facility of the Medical Faculty, University of Münster, Germany. Standard rodent chow and water were available *ad libitum* throughout the study and shredded paper was available for nest building. Mice were housed using a 14:10 light:dark cycle starting at 06:00 a.m. This study was carried out in strict accordance to the German Council on Animal Care under a specifically approved protocol by the ethics committee LANUV, NRW, Germany (protocol #84–02.04.2013.A007). All surgery was performed under isoflurane anesthesia, and all efforts were made to minimize suffering. 10<sup>6</sup> cells parental control and B16V<sup>shUst(16)</sup> cells in 70 µl PBS were injected s.c. into the right flanks of the mice. Mice and primary tumors were monitored every other day. Tumors were categorized as + < 0.5 cm<sup>3</sup>, ++ = 0.5–1 cm<sup>3</sup>, +++ > 1 cm<sup>3</sup>. Animals found with clinical signs, like weight loss or respiratory difficulty, were subjected to euthanasia. Euthanasia was carried out with an overdose of inhalant anesthetic followed by cervical dislocation. Primary tumors were removed after 15–21 days because of the size of the tumor (tumor size: B16V from 0.09 to 1.78 mg and B16V<sup>shUst(16)</sup> from 0.1 to 3.9 mg) and weighed. Metastasis was monitored over a 6–7 week period followed by autopsies of the sacrificed animals [38]. Animals found with clinical signs were subjected to euthanasia. Pulmonary metastasis was evaluated macroscopically.

## Statistical analysis


Statistical evaluation was performed with GraphPad Prism4 using Student's *t*-test.  $P < 0.05$  was considered as significant.

## Results

### Silencing *Ust* in B16V cells

To demonstrate that human cancer cells express UST we analyzed the human melanoma cell lines HT168-M1, HT199 and MV3 [29, 31] by qRT-PCR. All 3 cell lines express human *UST* (S1 Fig) with  $\Delta$ CT ranging from ~1.67 to ~3.69. We previously published the *Ust* expression of CHO-K1 cells which showed a  $\Delta$ CT value of ~3.4 [5].

B16V melanoma cells, which also express *Ust* mRNA ( $\Delta$ CT of ~4) and protein (Fig 1A and 1B), have a highly metastatic potential *in vivo* [39]. To define the functional contribution of Ust to melanoma metastasis, lentiviral particles carrying shRNAs (shUst) were used to knock-down *Ust* in B16V cells. We also generated the respective mock controls. 20 clones were isolated and the *Ust* knock-down efficiency was determined. B16V and B16V<sup>mock</sup> had similar *Ust* expression. Clone 6 (B16V<sup>shUst(6)</sup>) and 16 (B16V<sup>shUst(16)</sup>) showed a down-regulation of *Ust* mRNA by ~44% and ~80% (Fig 1A) and were further analyzed. Protein amounts revealed a reduction by ~37% and ~63%, respectively, for the two tested clones (Fig 1B; upper panel). Of note, B16V control and B16V<sup>mock</sup> cells displayed no differences in the amount of Ust protein, so that B16V cells could be used as a control. Next, we determined sulfotransferase activity of cells. The substrate chondroitin 6-sulfate is converted to chondroitin 2,6 sulfate by Ust. B16V cells



**Fig 1. Modulation of Ust expression in melanoma cell lines.** (A) Total RNA and cell lysates of B16V control, mock transfected B16V (B16V<sup>mock</sup>) and clones of B16V<sup>shUst</sup> were analyzed by qRT-PCR. *Ust* expression was normalized to the housekeeping genes  $\beta$ -actin and ubiquitin. (B) Immunoblots of protein lysates were probed for Ust and  $\beta$ -actin of different transfected B16V melanoma cell lines (lower panel). Band intensities were quantified and Ust signals were normalized to  $\beta$ -actin (upper panel). (C) Sulfotransferase activity of the cell lines B16V, B16V<sup>shUst(6)</sup> and B16V<sup>shUst(16)</sup>. (D) Highly-sulfated cell surface CS/DS disaccharide composition of the cell lines B16V, B16V<sup>shUst(6)</sup> and B16V<sup>shUst(16)</sup>. Data shown are the mean  $\pm$ SEM ( $n \geq 4$ ); \*\*,  $P < 0.01$ , \*\*\*,  $P < 0.001$ ).

doi:10.1371/journal.pone.0170054.g001


displayed a total sulfotransferase activity of  $0.61 \pm 0.06$  pmol/min/ $\mu$ g. Both B16V<sup>shUst(6)</sup> ( $0.47 \pm 0.01$  pmol/min/ $\mu$ g) and B16V<sup>shUst(16)</sup> ( $0.34 \pm 0.04$  pmol/min/ $\mu$ g) showed a significantly lower activity (Fig 1C) correlating with the *Ust* knock-down. FACE analysis of the GAGs after the sulfotransferase assay confirmed the reduced amount of  $\Delta$ HexUA(2S)-GalNAc(6S) ( $\Delta$ Di2,6S-units) for both cell clones (S2A and S2B Fig).

The reduced *Ust* enzyme activity affected also the 2-O sulfated units at the cell surface. Highly-sulfated CS/DS purified from *Ust* knock-down cells lack detectable amounts of 2-O sulfated disaccharide units compared to the control cells (Fig 1D). Of note, the uronic acid content of the highly-sulfated cell surface CS/DS was similar for all three tested cell lines (S2C Fig). For B16V we detected 5 different disaccharide units, for B16V<sup>shUst(6)</sup> and B16V<sup>shUst(16)</sup> only 4 different disaccharide units. The percentages of  $\Delta$ HexUA-GalNAc ( $\Delta$ Di0S) and  $\Delta$ HexUA-GalNAc(4S) ( $\Delta$ Di4S) were similar in all three cell lines (Fig 1D).  $\Delta$ HexUA-GalNAc(6S) ( $\Delta$ Di6S) and  $\Delta$ HexUA-GalNAc(4S,6S) ( $\Delta$ Di4,6S) units displayed slight alterations. Interestingly, we did not detect any mono-sulfated  $\Delta$ Di2S-units in B16V cells. B16V cells contained  $\sim 8 \pm 0.8\%$  of di-sulfated  $\Delta$ HexUA(2S)-GalNAc(4S or 6S) ( $\Delta$ Di2,XS-units (X = 4 or 6)). HPLC analysis of total GAGs confirmed that the amount of  $\Delta$ Di4S in the total CS/DS did not vary between the cell lines, indicating a similar amount of DS (S2D Fig). Furthermore, the  $\Delta$ Di2,XS detected by FACE was confirmed by HPLC as  $\Delta$ Di2,4S. As expected, a  $\sim 63\%$  *Ust* protein

reduction in B16V<sup>shUst(16)</sup> abolished 2-O sulfated units (Fig 1D). For ~37% reduction of Ust we could not detect 2-O sulfated units by FACE. This can be explained by the limit of detection because the enzyme activity test showed also a ~40% less 2,6-O sulfation for B16V<sup>shUst(6)</sup> cells (S2A and S2B Fig). HS analysis revealed no alterations in the disaccharide composition (S2E Fig). These data show that we generated B16V melanoma cell lines with different levels of Ust and 2-O sulfated CS/DS GAGs on the cell surface.

### Functional characterization of the B16V<sup>shUst</sup> cells in vitro

Previously, the importance of cell surface DS [20] and 2-O sulfation [5, 23] for cell migration was reported. In the present study, scratch assays showed that B16V melanoma cells close the gap within 20h (Fig 2A). The reduction of Ust led to a significantly slower migration of B16V<sup>shUst(6)</sup> and B16V<sup>shUst(16)</sup> cells on plastic. Fgf2 is a critical regulator of melanoma progression and it is expressed by melanoma cells [40]. However, Fgf2 addition had no impact on cell migration (Fig 2A and 2B). To exclude an overlap of migration and proliferation, BrdU incorporation was assessed. Within 24h under serum-free conditions B16V and B16V<sup>shUst(6)</sup> cells



**Fig 2. Migration of B16 melanoma cell lines.** (A) Scratch assays were performed on B16V control, B16V<sup>shUst(6)</sup> and B16V<sup>shUst(16)</sup>. Confluent cells were starved and wounded prior to Fgf2 treatment. Representative pictures are shown for 0 and 20h (Bar = 100 µm). (B) Quantification of the wound scratch assay shown in (A). Data are expressed as a mean±SD of three independent experiments (n = 8 for each condition). (C) Proliferation of the B16V cell lines measured by BrdU incorporation for 20h. (D) Paths of four migrating cells of B16V control and B16V<sup>shUst(16)</sup> evaluated by time lapse-microscopy. (E) Quantifications of the migration of control and B16V<sup>shUst(16)</sup> velocity (Supporting Information S3 and S4 Figs) and (F) total distance covered on murine wild-type fibroblast matrices (three independent experiments, mean±SD, 32 control cells and 54 B16V<sup>shUst(16)</sup> cells, \*, P<0.05, \*\*, P<0.01, \*\*\*, P<0.001).

doi:10.1371/journal.pone.0170054.g002




showed similar proliferation rates, only B16V<sup>shUst(16)</sup> cells displayed a significant increase in proliferation (Fig 2C). Therefore, we can conclude, that proliferation does not interfere with migration. Since molecular analysis of clone 6 showed no significant but detectable changes, we mostly show clone 16 in the following.

To get closer to an *in vivo* situation we used skin fibroblasts which were cultured for 10 days to deposit their own 3D ECM. Migration of B16V cell lines was monitored by time-lapse microscopy (movies S3 and S4 Figs). Tracking single cells on the ECM showed that B16V<sup>shUst(16)</sup> cells migrated significantly more slowly ( $0.30 \pm 0.12 \mu\text{m}/\text{min}$ ) than controls ( $0.35 \pm 0.09 \mu\text{m}/\text{min}$ ) (Fig 2D and 2E). Furthermore, controls covered significantly longer distances than B16V<sup>shUst(16)</sup> cells (Fig 2F).

These results show that Ust and consequently CS/DS 2-O sulfation affect melanoma cell migration. To clarify the altered migration of the B16V<sup>shUst</sup> cell lines we analyzed cell adhesion.

### Lack of Ust in B16V affects adhesion to fibronectin

Cell surface GAGs influence adhesion and migration of cancer cells [41]. Assessment of B16V<sup>shUst</sup> cell adhesion to plastic showed a significant reduction when compared to control (S5A Fig). Integrins, such as  $\alpha 5 \beta 1$ , are involved in adhesion to fibronectin [25]. After 1h and 6h, B16V cell adhesion to fibronectin was significantly higher compared to the B16V<sup>shUst</sup> cell lines (Fig 3A). To demonstrate the influence of sulfation, cells were pre-treated with 30 mM NaClO<sub>3</sub>. Chlorate treatment leads to an inhibition of the 3'-phosphadenosine-5-phosphosulfate synthesis and reduction of the sulfate content of cell surface GAG [42]. Of note, after chlorate treatment B16V<sup>shUst(16)</sup> cell adhesion monitored at the time point 1h was significantly lower



**Fig 3. Adhesion of the B16V melanoma cell lines to fibronectin.** (A) Adhesion of B16V control, B16V<sup>shUst(6)</sup> and B16V<sup>shUst(16)</sup> cells in fibronectin-coated wells. (B) Adhesion of B16V control and B16V<sup>shUst(16)</sup> cells to fibronectin after 1h after treatment with chondroitin ABC lyase (ABCCase), heparitinase (Hep-Mix) and ABCCase+Hep-Mix. (C) Adhesion of B16V and B16V<sup>shUst(16)</sup> cells to fibronectin for 1h after blocking of  $\alpha \nu \beta 3$  integrin. The integrins were blocked with the  $\alpha \nu$  integrin blocking antibody, isotype control IC-1 (Rat IgG1,  $\kappa$  as control against  $\alpha \nu$  integrin),  $\beta 3$  integrin blocking antibody and isotype control IC-2 (Armenian Hamster IgG towards  $\beta 3$  integrin). (D) Adhesion of B16V and B16V<sup>shUst(16)</sup> cells to fibronectin after blocking with  $\alpha 5$  integrin blocking antibody, isotype control IC-3 (Rat IgG2a,  $\kappa$  as control for  $\alpha 5$  integrin) and  $\beta 1$  integrin blocking antibody and isotype control IC-2 (Armenian Hamster IgG for  $\beta 1$  integrin). Each experiment was performed in duplicates,  $n = 3$ , mean  $\pm$  SD (A, B), mean  $\pm$  SEM (C, D), \*,  $P < 0.05$ , \*\*,  $P < 0.01$ , \*\*\*,  $P < 0.001$ .

doi:10.1371/journal.pone.0170054.g003


compared to B16V cells (S5B Fig). To narrow down the type of GAGs involved in adhesion, cell surface CS/DS was digested with chondroitin ABC lyase and HS with heparitinase [5]. Enzymatic digestion of CS/DS or HS led to a significantly reduced adhesion of B16V cells compared to the non-treated cells after 1h. Upon digestion of cell surface CS/DS (ABCCase), but not HS, we observed a significant difference between control and B16V<sup>shUst(16)</sup> cells. Digestion of both CS/DS (ABCCase) and HS (Hep-Mix) reduced adhesion of both cell types (Fig 3B). To determine which integrin dimer is responsible for the impaired adhesion of the B16V<sup>shUst(16)</sup> cells, we used specific blocking antibodies for  $\alpha\beta3$  and  $\alpha5\beta1$  integrin and the respective isotype controls. Blocking of  $\alpha\upsilon$  or  $\beta3$  integrin had no impact on the adhesion of either B16V cells or B16V<sup>shUst(16)</sup> cells to fibronectin when cells were compared to their isotype treated controls or the non-treated cells (Fig 3C). In contrast, blocking of  $\alpha5$  or  $\beta1$  integrin significantly reduced adhesion of B16V to fibronectin compared to isotype treated controls or the non-treated cells (Fig 3D). Interestingly, B16V<sup>shUst(16)</sup> cells showed still basal adhesion compared to isotopic treated control or the non-treated cells (Fig 3D). The results indicate that  $\alpha5\beta1$  integrin, but not  $\alpha\upsilon\beta3$  integrin, mediates adhesion of B16V cells to fibronectin.

### *Ust* knock-down influences *Itga5* and *Fgfr1* expression in melanoma cells

To investigate the connection of CS/DS 2-O sulfation and  $\alpha5$  integrin-mediated adhesion *Itga5* expression was analyzed. For control and mock transfected B16V cells *Itga5* expression was similar. B16V<sup>shUst(6)</sup> (-20%) and B16V<sup>shUst(16)</sup> cells displayed a reduction, however, only B16V<sup>shUst(16)</sup> cells expressed significantly less *Itga5* (Fig 4A). Surprisingly, *Igtb1* and *Igtb3* expression was increased in B16V<sup>shUst</sup> cells (Table 1).

Control and B16V<sup>shUst(16)</sup> cells were seeded on fibronectin and analyzed by confocal microscopy. F-actin and the distribution of  $\alpha5$  integrin were evaluated after 3h (Fig 4B). In contrast to control, B16V<sup>shUst(16)</sup> cells showed less  $\alpha5$  integrin and altered F-actin distribution which might explain the impaired adhesion of the *Ust* knock-down cells (Fig 3B). The immunofluorescence results were supported by immunoblots for  $\alpha5$  integrin. Controls showed similar amounts of  $\alpha5$  integrin whereas for B16V<sup>shUst(16)</sup> cells  $\alpha5$  integrin was significantly reduced (Fig 4C). Again, B16V<sup>shUst(6)</sup> showed also a reduced amount of  $\alpha5$  integrin similar to the qRT-PCR data. Next, we determined the amount of  $\alpha5$  integrin on the cell surface by FACS analysis and observed no differences for all tested cell lines (S6A, S6B and S6C Fig). To link GAG sulfation to integrins the cells were treated with chlorate. Chlorate treatment depleted  $\alpha5$  integrin in both cell lines (Fig 4D), indicating a link between sulfation and  $\alpha5$  integrin. *Itga5* is known to be regulated by Fgf2 [43, 44]. Therefore, we used the specific inhibitor PD173074 to target FgfR1. Blocking FgfR1 for 6h led to a reduction of  $\alpha5$  integrin of control, mock, B16V<sup>shUst(6)</sup> and B16V<sup>shUst(16)</sup> cells (Fig 4E and 4F). Next, we analyzed *Fgfrs* transcripts and only *Fgfr1* and 3 showed higher expression levels. Interestingly, the expression levels of *Fgfr1* in the B16V cell lines were significantly reduced correlating with the decrease of *Ust*. *Fgfr3* was significantly increased only in the B16V<sup>shUst(16)</sup> cells (Fig 4G).

Next we determined the amount of FgfR1 and its activation in the B16 cell lines. An ELISA type assay showed a significant reduction of FgfR1 protein in the knock-down cells correlating with the amount of *Ust* (Fig 4H). Moreover, the activation of FgfR1-Y654 showed that both knock-down cell lines displayed significantly less phosphorylation compared to control and mock transfected B16V cells (Fig 4I). Therefore, we can conclude that, depending on *Ust* levels, *ITGa5* and *Fgfr1* expression is affected as well as the activation of FgfR1. In addition, 2-O sulfated CS/DS proteoglycans influence the function of  $\alpha5\beta1$  integrin and consequently cell adhesion to fibronectin.



**Fig 4.  $\alpha 5$  integrin expression in murine B16 cells.** (A) B16V cell lines analyzed for *Itga5* expression by qRT-PCR. *Itga5* expression was normalized to the housekeeping genes  $\beta$ -actin and *ubiquitin*. (B) Distribution of  $\alpha 5$  integrin on control and B16V<sup>shUst(16)</sup> cells seeded on fibronectin for 3 h.  $\alpha 5$  integrin (red), F-actin (green) and nuclei stained with DAPI (blue). Bar = 25  $\mu$ m. Protein extracts of control, B16V<sup>mock</sup>, B16V<sup>shUst(6)</sup> and B16V<sup>shUst(16)</sup> cell lines were subjected to immunoblotting. (C) Immunoblots were performed to detect  $\alpha 5$  integrin and  $\beta$ -actin (lower panel). Signal intensities were normalized to the loading control  $\beta$ -actin (upper panel) (n = 3–5 mean $\pm$ SEM, \*\*, P<0.01). (D) B16V control and B16V<sup>shUst(16)</sup> cells were starved overnight and treated with 30 mM NaClO<sub>3</sub> for 6h. Protein lysates were analyzed for  $\alpha 5$  integrin and the loading control  $\beta$ -actin (lower panel). (E) Control and B16V<sup>shUst(16)</sup> cells were starved overnight and treated with 20 mM PD173074 for 6h. Protein extracts were subjected to immunoblotting for  $\alpha 5$  integrin and  $\beta$ -actin. (F) Quantification of  $\alpha 5$  integrin after PD173074 treatment was obtained by ELISA with GAPDH as control. (G) B16V cell lines were analyzed for *FgfR1* and *FgfR3* expression by qRT-PCR and normalized to  $\beta$ -actin and *ubiquitin*. (H, I) B16V cell lines were analyzed for *FgfR1* and pY654*FgfR1* by ELISA. *FgfR1* was normalized to GAPDH and to total cell number. Data are shown as mean $\pm$ SD (n = 3, \*, P<0.05, \*\*, P<0.01, \*\*\*, P<0.001).

doi:10.1371/journal.pone.0170054.g004

## Melanoma cell lung metastasis is influenced by *Ust* expression


The metastatic potential is greatly affected by the expression levels of integrins. Therefore, we investigated the behavior of B16V<sup>shUst(16)</sup> cells *in vivo*. When control and B16V<sup>shUst(16)</sup> cells were inoculated into female syngenic C57BL/6 mice no difference in tumor growth was observed (Fig 5A; Table 2; n = 12 for control and 11 for B16V<sup>shUst(16)</sup>). 15–21 days after the resection of the primary tumor, mice were sacrificed and further analyzed. There was no difference in weight of the mice (control: 21.36 $\pm$ 2.1 g, B16V<sup>shUst(16)</sup> 22.54 $\pm$ 1.0 g). Macroscopic evaluation of lungs showed metastases in 6 out of 9 mice inoculated with control cells, whereas the 11 mice with B16V<sup>shUst(16)</sup> tumors showed no macroscopic lung metastasis (Table 2 and

**Table 1. Expression of integrins in B16 cell lines.**

Gene	Protein	Mock	B16V <sup>shUst(6)</sup>	B16V <sup>shUst(16)</sup>
<i>Itgb1</i>	$\beta 1$ integrin	1.43 $\pm$ 0.37	2.28 $\pm$ 0.32	3.6 $\pm$ 0.5
<i>Itgb3</i>	$\beta 3$ integrin	1.37 $\pm$ 0.25	2.23 $\pm$ 0.18	2.64 $\pm$ 0.37

B16V, B16V<sup>mock</sup>, B16V<sup>shUst(6)</sup> and B16V<sup>shUst(16)</sup> cells were analyzed for *Itgb1* and *Itgb3* expression by qRT-PCR. Expression was calculated as described in Materials & Methods (n = 6) and normalized to parental B16V cells. *Itgb1* expression levels are significantly increased in B16V<sup>shUst(16)</sup> cells compared to B16V<sup>mock</sup> cells. Data are presented as the Fold-change $\pm$ SEM.

doi:10.1371/journal.pone.0170054.t001



**Fig 5. Pulmonary metastasis of B16V cells and analysis of the primary tumors.** (A) Dissected control and B16V<sup>shUst(16)</sup> primary tumors (left panel) and their weight (right panel) measured after 15–21 days of inoculation (three independent experiments n = 13–15). (B) Macroscopic evaluation of lungs of mice after 6–7 weeks of primary tumor dissection. Three representative pictures of each control and B16V<sup>shUst(16)</sup> inoculated mice. (C) Representative blots of control and B16V<sup>shUst(16)</sup> primary tumor lysates for Ust,  $\alpha$ 5 integrin and  $\beta$ -actin as loading controls.

doi:10.1371/journal.pone.0170054.g005

Fig 5B). Notably, detection of lung metastasis was independent of the tumor size. Western blot analysis revealed a reduction of Ust and  $\alpha$ 5 integrin in the B16V<sup>shUst(16)</sup> tumors (Fig 5C). The amount of  $\beta$ 1 integrin in the tumor lysates was not altered (S7 Fig). These *in vivo* results support the *in vitro* observation of impaired B16V<sup>shUst(16)</sup> adhesion due to a reduced amount of  $\alpha$ 5 $\beta$ 1 integrin induced by the lack of Ust.

### UST in human melanoma MV3 cells

Our concept was supported by the results obtained with siRNA-mediated *UST* knock-down in human MV melanoma cells. *UST* siRNA transfection of MV cells caused an 80% reduction of *UST* mRNA (Fig 6A). In these cells *ITGa5* was also reduced by 70% (Fig 6B), and consequently adhesion to fibronectin (Fig 6C). These results show that CS/DS 2-O sulfation mediates  $\alpha$ 5 integrin expression via FgFR at least after *Ust* knock-down.

**Table 2. *In vivo* experiments using control and B16V<sup>shUst(16)</sup> cells in a C57BL/6 mice tumor metastasis model.**

Experiment	Mice per strain	Removal of primary tumor		Analyzed after 6–7 weeks		Lung metastasis <sup>§</sup>	
		Con	B16V <sup>shUst(16)</sup>	Con	B16V <sup>shUst(16)</sup>	Con	B16V <sup>shUst(16)</sup>
V1	5	3 (2 <sup>+</sup> )	3 (2 <sup>+</sup> )	2 (1 <sup>§</sup> )	3	1	0
V2	5	5	4 (1 <sup>#</sup> )	3 (2 <sup>§</sup> )	4	3	0
V3	5	4 (1 <sup>*</sup> )	4 (1 <sup>*</sup> )	4	4	2	0
Total	15	12	11	9	11	6	0

10<sup>6</sup> cells were injected and after 15–21 days primary tumors were removed. After 6–7 weeks mice were dissected and macroscopically evaluated for lung metastasis.

<sup>+</sup> mice died before tumor dissection


<sup>#</sup> mice no tumor developed

<sup>\*</sup> mice died during tumor dissection

<sup>§</sup> mice died during 7 weeks

<sup>§</sup> macroscopic evaluation

doi:10.1371/journal.pone.0170054.t002



**Fig 6. Human melanoma cells and *UST* knock-down.** Expression levels of *UST* (A) and *ITGA5* (B) in human MV3 melanoma cells after transient *UST* knock-down with siRNA. Expression was normalized to the housekeeping gene  $\beta$ -actin. (C) Adhesion to fibronectin of *UST* knock-down MV3 cells and the respective control. Data are shown as mean  $\pm$  SEM (n = 3, \*\*\*,  $P < 0.001$ ).


doi:10.1371/journal.pone.0170054.g006

Our results show that Ust and 2-O sulfation levels of CS/DS affect the synthesis of *Itga5* and *FgfR1* and, in addition, the function of  $\alpha 5 \beta 1$  integrin which leads to impaired melanoma cell adhesion (Fig 7).

## Discussion

Migration of tumor cells is an important step during metastasis. The motility of melanoma cells contributes to their highly invasive and metastatic potential. Melanoma cells display a shift from HS and DS to CS [13]. However, the function of the fine structure of the 2-O sulfation of the CS/DS chains and the respective enzymes involved, especially Ust, are not known. So far the function of Ust has been studied during brain development or under physiological conditions [5, 19]. CHO-K1 cells express Ust which subsequently leads to CS/DS 2-O sulfation, later involved in Fgf-2-induced migration [5]. Recently, a patient with a microdeletion on chromosome 6q25.1 was described with among other symptoms an Ehlers-Danlos syndrome in skin [45]. The microdeletion included the lack of human UST gene indicating that the minor sulfation of CS/DS affects also the organization of the extracellular matrix, similar to the DS [46]. Understanding the impact of Ust and 2-O sulfation might identify potential therapeutic targets in melanoma metastasis.

We used an experimental metastatic model of B16 cells which has the advantage of forming a primary orthologue tumor followed by metastasis from the skin to the lung [39]. Our *in vivo*



**Fig 7. Model depicting the potential role of Ust and CS/DS 2-O sulfation in melanoma metastasis.** Ust knock-down reduces 2-O sulfation of CS/DS proteoglycans and affects *Itga5* expression possibly via FgfR1. The consequence of reduced sulfation is an impaired adhesion. α5-AB: blocking antibody for α5 integrin. For additional details refer to the text.

doi:10.1371/journal.pone.0170054.g007

experiments show a marked inhibition of pulmonary metastasis after the knock-down of *Ust* in B16V cells. The importance of the CS/DS fine structure has been shown in the LLC pulmonary metastasis model, where the knock-down of *Chst15* reduced ΔDi4,6S units and consequently the transmigration of cells from the blood into the lung tissue [17]. A reduced proliferation was observed for the LCC *Chst15* knock-down cells [17] or when DS was removed from melanoma cells [14]. In contrast, *in vitro* Ust knock-down increased proliferation in CHO-K1 [5] and B16V cells. *In vivo* we observed a similar size of the tumors for the B16V model which could be explained by similar amounts of ΔDi4,6S units. Of note, B16 cells contain 1.5 times more DS than LCC cells [18] indicating that adhesion and migration of melanoma cells could be influenced by 2-O sulfated CS/DS. Under physiological conditions, Ust has been shown to be important for *in vivo* cell migration and possibly development [19, 45].

The structures of GAGs influence migration, too. Aortic smooth muscle cells with reduced DS show a decrease in directional migration, although the velocity and the total distance are increased [20]. Of note, the reduction of DS in mice reduced also the 2-O sulfation of CS/DS [47]. Knock-down of DS-epimerase 1 and consequently DS in cancer cells also reduced migration [7]. Vice versa, CHO-K1 cells migrate faster when they overexpress Ust. B16V melanoma cells are highly metastatic [39] and display an increased velocity compared to CHO-K1 cells [5]. *Ust* knock-down in B16V cells consequently reduced migration, like *Chst15* knock-down in LCC cells [17]. Our observation that the amount of ΔDi4S-units was not affected and migration was opposed to smooth muscle cells with reduced DS might indicate that the amount of DS on the cell surface of B16V cell lines is not affected by the *Ust* knock-down.

*Ust* knock-down in CHO-K1 cells and fibroblasts also results in an impaired migration as previously reported for neuronal outgrowth [5, 19, 23]. The residual migration of B16V<sup>shUst(6)</sup> cells, in contrast to B16V<sup>shUst(16)</sup>, can be explained by the presence of ΔDi4,6S units [17] and



the impact of the level of 2-O sulfation. *In vivo*, for HS not only the amount of sulfation but also the HS structure affects hedgehog signaling during development [48]. Migration on a complex ECM generated by fibroblasts requires integrins that recognize several matrix ligands including fibronectin (e.g.  $\alpha 5\beta 1$ ,  $\alpha \nu\beta 3$ ,  $\alpha 4\beta 1$ ) or collagens ( $\alpha 1\beta 1$ ,  $\alpha 2\beta 1$ ). Previously, we showed that the lack of decorin and the reduced amount of 2-O sulfated CS/DS in fibroblasts lead to an increase in  $\beta 1$  integrin [23, 33]. Melanoma cells express  $\alpha 5\beta 1$  and  $\alpha \nu\beta 3$  integrin which are involved in adhesion and migration [26] and are tightly regulated [24]. Overexpression of miR-148b in melanoma cells significantly inhibited metastasis by reducing *ITGa5* [49]. In contrast to decorin-deficient fibroblasts, B16V *Ust* knock-down cells displayed a reduction in  $\alpha 5$  integrin. B16V cell adhesion to fibronectin was only reduced by blocking  $\alpha 5\beta 1$  but not  $\alpha \nu\beta 3$ . The cell surface amount of  $\alpha 5$  integrin was not altered in B16V *Ust* knock-down cells indicating that 2-O CS/DS sulfation functions as a structural component involved in adhesion. Various studies showed that cell surface CS and DS and their structures have an impact on cancer cell adhesion [7, 14, 15, 17, 41]. One might speculate that the level of CS/DS 2-O sulfation on the cell surface modulates  $\alpha 5\beta 1$  integrin conformation and fibronectin binding. This speculation can be supported by a recent publication about different distinct global conformations of  $\alpha 5\beta 1$  integrin which determine adhesive and non-adhesive function to fibronectin. Under conditions in which the bent-closed conformation predominates,  $\alpha 5\beta 1$  integrin impairs adhesion to fibronectin in a K562 cell line [50].

As modulating signaling events, *Ust* knock-down and consequently, CS/DS 2-O sulfation are associated with the expression of *Itga5* and *FgfR1*. The reduced expression of *Itga5* and *FgfR1* can be explained by the function of CS/DS as low affinity receptors for different growth factors [1, 2, 7] and therefore affecting signaling. This hypothesis is supported by a reduced *Itga5* expression either after inhibition of cell surface sulfation or by blocking *FgfR1*. Moreover, also *FgfR1* and its activation are reduced in B16 *Ust* knock-down cells. The link of  $\alpha 5$  integrin, *Fgf2* and *FgfR* has been demonstrated for angiogenesis [43] and in 3T3 fibroblasts [44]. In addition, the aggressiveness of melanoma is due to *Fgf2* induced  $\alpha 5$  integrin expression [28]. Under physiological conditions *Fgf2* signaling requires GAGs [1] and we could show that 2-O sulfated CS/DS are involved in migration [5]. A possible downstream mechanism could be the transcription factor Twist-1 which has been recently shown to induce *Itga5* expression and leads to epithelial-mesenchymal transition [51]. The link between reduced Twist-1 expression, lack of DS and adhesion to fibronectin has been shown for *Xenopus* neural crest cells [52]. Of note, adhesion of B16V<sup>shUst(16)</sup> cells was significantly reduced by either inhibiting CS/DS sulfation or by digesting cell surface GAGs.

To support a possible role of *Ust* in melanoma, we tested three metastasizing human melanoma cell lines, MV3 [31], HT199 and HT168M [30] that all express *UST*. The biological relevance of the data obtained with mouse melanoma cells is supported by the human melanoma cell line MV3 which expresses *UST*. siRNA-mediated *UST* knock-down in MV3 cells also showed a reduction in *ITGa5* and adhesion.

Overall our data propose *Ust* and consequently 2-O sulfated CS/DS as a regulator of adhesion via the amount and activation of *FgfR1* and the expression of *Itga5* in melanoma cells (Fig 7). In addition, the amount of 2-O sulfated CS/DS influences  $\alpha 5\beta 1$  integrin function in melanoma cells indicating that *Ust* could be a potential marker for melanoma metastasis and a target for a therapeutic approach.

## Supporting Information

**S1 Fig. *UST* expression in melanoma cell lines.** qRT-PCR for *UST* of three human melanoma cell lines with high metastasizing potential and murine B16V cells. HT168-M1, HT199

(Ladányi et al., 2001) and MV3 cells (van Muijen et al., 1991) were previously described. HT168-M and HT199 revealed similar metastatic potential after intra-splenic injection (Ladányi et al., 2001). All tested cell lines express *UST*.  $\Delta$ CT values show that all three human cell lines express more *UST* compared to B16V cells.

(JPG)

**S2 Fig. Characterization of B16<sup>shUst</sup> cell lines.** B16 cell lysates were subjected to the sulfotransferase assay (see [Materials and Methods](#)) followed by disaccharide analysis by FACE. CS6S was used as a substrate to determine the sulfotransferase activity and to obtain  $\Delta$ Di2,6S units. The gel following FACE does not allow to distinguish between  $\Delta$ Di2,6S and  $\Delta$ Di2,4S therefore, we used  $\Delta$ Di2,XS. (A) Borate gel shows a reduced amount of  $\Delta$ Di2,XS in both B16V<sup>shUst</sup> cell lines indicating a reduction in 2-O sulfotransferase activity due to the *Ust* knock-down. (B) The quantification of the signals (panel A) shows 40% less 2-O sulfated disaccharides for B16VshUst(6) and 70% less for B16VshUst(6). The FACE analysis supported the result obtained by the enzyme activity test (see [Fig 1C](#)). (C) Uronic acid content of the three B16V cell lines (n = 3). (D) Quantification of 4-sulfated disaccharides ( $\Delta$ Di4S) derived from total cell surface CS/DS and (E) HS disaccharide analysis of B16V and B16VshUst(16) cells (n = 3).

(TIF)

**S3 Fig. Movie of the migration of control B16V cells (B) on 3D matrices generated by fibroblasts over 10 days.** To obtain a collagen-rich ECM fibroblasts were cultured in the presence of ascorbate-2-phosphate. The time-lapse microscope took images in 5 min intervals for 2h.

(MOV)

**S4 Fig. Movie of the migration of B16<sup>shUst(16)</sup> cells on 3D matrices generated by fibroblasts over 10 days.** To obtain a collagen-rich ECM fibroblasts were cultured in the presence of ascorbate-2-phosphate. The time-lapse microscope took images in 5 min intervals for 2h.

(MOV)

**S5 Fig. Adhesion of control B16V and B16V<sup>shUst(16)</sup> cells.** (A) Time course for the cell adhesion to plastic. (B) Cell adhesion for 1 h to fibronectin after treatment with 30 mM chlorate for 6 h to inhibit GAG sulfation. Both regiments lead to a reduction of adhesion of the B16V cells to basal levels of B16V<sup>shUst(16)</sup> cells, indicating that CS/DS sulfation is involved in adhesion to fibronectin.

(TIF)

**S6 Fig. Cell surface  $\alpha$ 5 integrin determined by FACS.** Histogram of cell surface  $\alpha$ 5 integrin expression in B16V, B16V<sup>mock</sup>, B16V<sup>shUst(6)</sup> and B16V<sup>shUst(16)</sup> cell lines. Living cells were stained with (A) the antibody CD49e-Alexa647 or (B) the isotype control and subjected to FACS analysis. (C) Unstained cells were used as control. The histograms are one out of three representative experiments and display the same amount of  $\alpha$ 5 integrin on the cell surface of the 4 cell lines (n = 3).

(TIF)

**S7 Fig. Detection of  $\beta$ 1 integrin in the tumors.** Immuno blots of three control and three B16V<sup>shUst(16)</sup> primary tumors lysates for  $\beta$ 1 integrin and  $\beta$ -actin as loading control. The  $\beta$ 1 integrin blot was used after stripping. Therefore, the loading control  $\beta$ -actin is the same as in [Fig 5C](#).

(TIF)

## Acknowledgments

We thank Margret Bahl and Frauke Spiecker for their technical assistance, the IZKF core unit of the Medical Faculty of University of Münster for the qRT-PCR and the Core Facility Cell Sorting (Dr. M. Ballmaier) of the Medical School Hannover. This work was financially supported by the German Research Foundation (SE1431/3-1) to DGS, German Cancer Aid (#111262) to DGS and CS and the German Research Foundation—GRK 1549 International Research Training Group ‘Molecular and Cellular GlycoSciences’ to KN.

## Author Contributions

**Conceptualization:** DGS.

**Data curation:** DGS.

**Formal analysis:** KN DS CS DGS.

**Funding acquisition:** DGS CS KN.

**Investigation:** KN.

**Methodology:** DGS KN JH CS DS.

**Project administration:** KN DGS.

**Resources:** AL.

**Supervision:** DGS.

**Validation:** KN CS DS JH DGS.

**Visualization:** KN DGS.

**Writing – original draft:** DGS KN.

**Writing – review & editing:** KN DS JH AL CS DGS.

## References

1. Fuster M.M. & Esko J.D. (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. *Nat. Rev. Cancer.* 5 526–542. doi: [10.1038/nrc1649](https://doi.org/10.1038/nrc1649) PMID: [16069816](https://pubmed.ncbi.nlm.nih.gov/16069816/)
2. Afratis N., Gialeli C., Nikitovic D., Tsegenidis T., Karousou E., Theocharis A.D. et al. (2012) Glycosaminoglycans: key players in cancer cell biology and treatment. *FEBS J.* 279 1177–1197. doi: [10.1111/j.1742-4658.2012.08529.x](https://doi.org/10.1111/j.1742-4658.2012.08529.x) PMID: [22333131](https://pubmed.ncbi.nlm.nih.gov/22333131/)
3. Seidler D.G. (2012) The galactosaminoglycan-containing decorin and its impact on diseases. *Curr. Opin. Struct. Biol.* 22 578–582. doi: [10.1016/j.sbi.2012.07.012](https://doi.org/10.1016/j.sbi.2012.07.012) PMID: [22877511](https://pubmed.ncbi.nlm.nih.gov/22877511/)
4. Taylor K.R., Rudisill J.A. & Gallo R.L. (2005) Structural and sequence motifs in dermatan sulfate for promoting fibroblast growth factor-2 (FGF-2) and FGF-7 activity. *J. Biol. Chem.* 280 5300–5306. doi: [10.1074/jbc.M410412200](https://doi.org/10.1074/jbc.M410412200) PMID: [15563459](https://pubmed.ncbi.nlm.nih.gov/15563459/)
5. Nikolovska K., Spillmann D. & Seidler D.G. (2015) Uronyl 2-O sulfotransferase potentiates Fgf2-induced cell migration. *J. Cell. Sci.* 128 460–471. doi: [10.1242/jcs.152660](https://doi.org/10.1242/jcs.152660) PMID: [25480151](https://pubmed.ncbi.nlm.nih.gov/25480151/)
6. Esko J.D. & Selleck S.B. (2002) Order out of chaos: assembly of ligand binding sites in heparan sulfate. *Annu. Rev. Biochem.* 71 435–471. doi: [10.1146/annurev.biochem.71.110601.135458](https://doi.org/10.1146/annurev.biochem.71.110601.135458) PMID: [12045103](https://pubmed.ncbi.nlm.nih.gov/12045103/)
7. Malmstrom A., Bartolini B., Thelin M.A., Pacheco B. & Maccarana M. (2012) Iduronic acid in chondroitin/dermatan sulfate: biosynthesis and biological function. *J. Histochem. Cytochem.* 60 916–925. doi: [10.1369/0022155412459857](https://doi.org/10.1369/0022155412459857) PMID: [22899863](https://pubmed.ncbi.nlm.nih.gov/22899863/)
8. Mizumoto S., Yamada S. & Sugahara K. (2015) Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins. *Curr. Opin. Struct. Biol.* 34 35–42. doi: [10.1016/j.sbi.2015.06.004](https://doi.org/10.1016/j.sbi.2015.06.004) PMID: [26164146](https://pubmed.ncbi.nlm.nih.gov/26164146/)

9. Nakao M., Shichijo S., Imaizumi T., Inoue Y., Matsunaga K., Yamada A. et al. (2000) Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. *J. Immunol.* 164 2565–2574. PMID: [10679095](#)
10. Kobayashi M., Sugumaran G., Liu J., Shworak N.W., Silbert J.E. & Rosenberg R.D. (1999) Molecular cloning and characterization of a human uronyl 2-sulfotransferase that sulfates iduronyl and glucuronyl residues in dermatan/chondroitin sulfate. *J. Biol. Chem.* 274 10474–10480. PMID: [10187838](#)
11. Garrigues H.J., Lark M.W., Lara S., Hellstrom I., Hellstrom K.E. & Wight T.N. (1986) The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface. *J. Cell Biol.* 103 1699–1710. PMID: [2430975](#)
12. Wegrowski Y. & Maquart F.X. (2006) Chondroitin sulfate proteoglycans in tumor progression. *Adv. Pharmacol.* 53 297–321. doi: [10.1016/S1054-3589\(05\)53014-X](#) PMID: [17239772](#)
13. Smetsers T.F., van de Westerlo E.M., ten Dam G.B., Overes I.M., Schalkwijk J., van Muijen G.N. et al. (2004) Human single-chain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis. *J. Invest. Dermatol.* 122 707–716. doi: [10.1111/j.0022-202X.2004.22316.x](#) PMID: [15086557](#)
14. Denholm E.M., Lin Y.Q. & Silver P.J. (2001) Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion. *Eur. J. Pharmacol.* 416 213–221. PMID: [11290371](#)
15. Cooney C.A., Jousheghany F., Yao-Borengasser A., Phanavanh B., Gomes T., Kieber-Emmons A.M. et al. (2011) Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. *Breast Cancer Res.* 13 R58. doi: [10.1186/bcr2895](#) PMID: [21658254](#)
16. Li F., Ten Dam G.B., Murugan S., Yamada S., Hashiguchi T., Mizumoto S., et al. (2008) Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells. *J. Biol. Chem.* 283 34294–34304. doi: [10.1074/jbc.M806015200](#) PMID: [18930920](#)
17. Mizumoto S., Watanabe M., Yamada S. & Sugahara K. (2013) Expression of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase involved in chondroitin sulfate synthesis is responsible for pulmonary metastasis. *Biomed. Res. Int.* 2013 656319. doi: [10.1155/2013/656319](#) PMID: [23555092](#)
18. Mizumoto S., Takahashi J. & Sugahara K. (2012) Receptor for advanced glycation end products (RAGE) functions as receptor for specific sulfated glycosaminoglycans, and anti-RAGE antibody or sulfated glycosaminoglycans delivered in vivo inhibit pulmonary metastasis of tumor cells. *J. Biol. Chem.* 287 18985–18994. doi: [10.1074/jbc.M111.313437](#) PMID: [22493510](#)
19. Ishii M. & Maeda N. (2008) Oversulfated chondroitin sulfate plays critical roles in the neuronal migration in the cerebral cortex. *J. Biol. Chem.* 283 32610–32620. doi: [10.1074/jbc.M806331200](#) PMID: [18819920](#)
20. Bartolini B., Thelin M.A., Svensson L., Ghiselli G., van Kuppevelt T.H., Malmström A. et al. (2013). Iduronic acid in chondroitin/dermatan sulfate affects directional migration of aortic smooth muscle cells. *PLoS One* 8 e66704. doi: [10.1371/journal.pone.0066704](#) PMID: [23843960](#)
21. Kwok J.C., Warren P. & Fawcett J.W. (2012) Chondroitin sulfate: a key molecule in the brain matrix. *Int. J. Biochem. Cell Biol.* 44 582–586. doi: [10.1016/j.biocel.2012.01.004](#) PMID: [22265655](#)
22. Keire P.A., Bressler S.L., Mulvihill E.R., Starcher B.C., Kang I., Wight T.N. (2016) Inhibition of versican expression by siRNA facilitates tropoelastin synthesis and elastic fiber formation by human SK-LMS-1 leiomyosarcoma smooth muscle cells in vitro and in vivo. *Matrix Biol.* 50 67–81. doi: [10.1016/j.matbio.2015.12.010](#) PMID: [26723257](#)
23. Nikolovska K., Renke J.K., Jungmann O., Grobe K., Iozzo R.V., Zamfir A.D. et al. (2014) A decorin-deficient matrix affects skin chondroitin/dermatan sulfate levels and keratinocyte function. *Matrix Biol.* 35 91–102. doi: [10.1016/j.matbio.2014.01.003](#) PMID: [24447999](#)
24. Morgan M.R., Byron A., Humphries M.J. & Bass M.D. (2009) Giving off mixed signals—distinct functions of alpha5beta1 and alphavbeta3 integrins in regulating cell behaviour. *IUBMB Life* 61 731–738. doi: [10.1002/iub.200](#) PMID: [19514020](#)
25. Schaffner F., Ray A.M. & Dontenwill M. (2013) Integrin alpha5beta1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. *Cancers (Basel)* 5 27–47.
26. McKenzie J.A., Liu T., Jung J.Y., Jones B.B., Ekiz H.A., Welm A.L. et al. (2013) Survivin promotion of melanoma metastasis requires upregulation of alpha5 integrin. *Carcinogenesis* 34 2137–2144. doi: [10.1093/carcin/bgt155](#) PMID: [23640047](#)
27. McKenzie J.A., Liu T., Goodson A.G. & Grossman D. (2010) Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. *Cancer Res.* 70 7927–7937. doi: [10.1158/0008-5472.CAN-10-0194](#) PMID: [20807805](#)

28. Qian F., Zhang Z.C., Wu X.F., Li Y.P. & Xu Q. (2005) Interaction between integrin alpha(5) and fibronectin is required for metastasis of B16F10 melanoma cells. *Biochem. Biophys. Res. Commun.* 333 1269–1275. doi: [10.1016/j.bbrc.2005.06.039](https://doi.org/10.1016/j.bbrc.2005.06.039) PMID: [15979576](https://pubmed.ncbi.nlm.nih.gov/15979576/)
29. Supino R., Prosperi E., Formelli F., Mariani M. & Parmiani G. (1986) Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention. *Br. J. Cancer* 54 33–42. PMID: [3730255](https://pubmed.ncbi.nlm.nih.gov/3730255/)
30. Ladanyi A., Gallai M., Paku S., Nagy J.O., Dudas J., Timar J. et al. (2001) Expression of a decorin-like molecule in human melanoma. *Pathol. Oncol. Res.* 7 260–266. PMID: [11882905](https://pubmed.ncbi.nlm.nih.gov/11882905/)
31. van Muijen G.N., Jansen K.F., Cornelissen I.M., Smeets D.F., Beck J.L. & Ruiter D.J. (1991) Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice. *Int. J. Cancer* 48 85–91. PMID: [2019461](https://pubmed.ncbi.nlm.nih.gov/2019461/)
32. Bocian C., Urbanowitz A.K., Owens R.T., Iozzo R.V., Gotte M. & Seidler D.G. (2013) Decorin potentiates interferon-gamma activity in a model of allergic inflammation. *J. Biol. Chem.* 288 12699–12711. doi: [10.1074/jbc.M112.419366](https://doi.org/10.1074/jbc.M112.419366) PMID: [23460644](https://pubmed.ncbi.nlm.nih.gov/23460644/)
33. Jungmann O., Nikolovska K., Stock C., Schulz J.N., Eckes B., Riethmuller C. et al. (2012) The dermatan sulfate proteoglycan decorin modulates alpha2beta1 integrin and the vimentin intermediate filament system during collagen synthesis. *PLoS One* 7 e50809. doi: [10.1371/journal.pone.0050809](https://doi.org/10.1371/journal.pone.0050809) PMID: [23226541](https://pubmed.ncbi.nlm.nih.gov/23226541/)
34. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A. et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* 3 RESEARCH0034.
35. Seidler D.G., Breuer E., Grande-Allen K.J., Hascall V.C. & Kresse H. (2002) Core protein dependence of epimerization of glucuronosyl residues in galactosaminoglycans. *J. Biol. Chem.* 277 42409–42416. doi: [10.1074/jbc.M208442200](https://doi.org/10.1074/jbc.M208442200) PMID: [12207034](https://pubmed.ncbi.nlm.nih.gov/12207034/)
36. Seidler D.G., Mohamed N.A., Bocian C., Stadtmann A., Hermann S., Schafers K. et al. (2011) The role for decorin in delayed-type hypersensitivity. *J. Immunol.* 187 6108–6119. doi: [10.4049/jimmunol.1100373](https://doi.org/10.4049/jimmunol.1100373) PMID: [22043007](https://pubmed.ncbi.nlm.nih.gov/22043007/)
37. Stock C., Jungmann O. & Seidler D.G. (2011) Decorin and chondroitin-6 sulfate inhibit B16V melanoma cell migration and invasion by cellular acidification. *J. Cell. Physiol.* 226 2641–2650. doi: [10.1002/jcp.22612](https://doi.org/10.1002/jcp.22612) PMID: [21792923](https://pubmed.ncbi.nlm.nih.gov/21792923/)
38. Vahle A.K., Domikowsky B., Schwoppe C., Krahling H., Mally S., Schafers M. et al. (2014) Extracellular matrix composition and interstitial pH modulate NHE1-mediated melanoma cell motility. *Int. J. Oncol.* 44 78–90. doi: [10.3892/ijo.2013.2158](https://doi.org/10.3892/ijo.2013.2158) PMID: [24173371](https://pubmed.ncbi.nlm.nih.gov/24173371/)
39. Nakamura K., Yoshikawa N., Yamaguchi Y., Kagota S., Shinozuka K. & Kunitomo M. (2002) Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model. *Life Sci.* 70 791–798. PMID: [11833741](https://pubmed.ncbi.nlm.nih.gov/11833741/)
40. Loffek S., Zigrino P., Angel P., Anwald B., Krieg T. & Mauch C. (2005) High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1alpha and basic fibroblast growth factor-mediated mechanisms. *J. Invest. Dermatol.* 124 638–643. doi: [10.1111/j.0022-202X.2005.23629.x](https://doi.org/10.1111/j.0022-202X.2005.23629.x) PMID: [15737206](https://pubmed.ncbi.nlm.nih.gov/15737206/)
41. Fthenou E., Zong F., Zafiroopoulos A., Dobra K., Hjerpe A. & Tzanakakis G.N. (2009) Chondroitin sulfate A regulates fibrosarcoma cell adhesion, motility and migration through JNK and tyrosine kinase signaling pathways. *In Vivo* 23 69–76. PMID: [19368127](https://pubmed.ncbi.nlm.nih.gov/19368127/)
42. Keller K.M., Brauer P.R. & Keller J.M. (1989) Modulation of cell surface heparan sulfate structure by growth of cells in the presence of chlorate. *Biochemistry* 28 8100–8107. PMID: [2532538](https://pubmed.ncbi.nlm.nih.gov/2532538/)
43. Collo G. & Pepper M.S. (1999) Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. *J. Cell. Sci.* 112 (Pt 4) 569–578.
44. Klein S., Bikfalvi A., Birkenmeier T.M., Giancotti F.G. & Rifkin D.B. (1996) Integrin regulation by endogenous expression of 18-kDa fibroblast growth factor-2. *J. Biol. Chem.* 271 22583–22590. PMID: [8798427](https://pubmed.ncbi.nlm.nih.gov/8798427/)
45. Salpietro V., Ruggieri M., Mankad K., Di Rosa G., Granata F., Loddo I. et al. (2015) A de novo 0.63 Mb 6q25.1 deletion associated with growth failure, congenital heart defect, underdeveloped cerebellar vermis, abnormal cutaneous elasticity and joint laxity. *Am. J. Med. Genet. A.* 167 2042–2051.
46. Syx D., Van Damme T., Symoens S., Maiburg M.C., van de Laar I., Morton J. et al. (2015) Genetic heterogeneity and clinical variability in musculocontractural Ehlers-Danlos syndrome caused by impaired dermatan sulfate biosynthesis. *Hum. Mutat.* 36 535–547. doi: [10.1002/humu.22774](https://doi.org/10.1002/humu.22774) PMID: [25703627](https://pubmed.ncbi.nlm.nih.gov/25703627/)
47. Maccarana M., Kalamajski S., Kongsgaard M., Magnusson S.P., Oldberg A. & Malmstrom A. (2009) Dermatan sulfate epimerase 1-deficient mice have reduced content and changed distribution of iduronic

- acids in dermatan sulfate and an altered collagen structure in skin. *Mol. Cell. Biol.* 29 5517–5528. doi: [10.1128/MCB.00430-09](https://doi.org/10.1128/MCB.00430-09) PMID: [19687302](https://pubmed.ncbi.nlm.nih.gov/19687302/)
48. Dierker T., Bachvarova V., Krause Y., Li J.P., Kjellen L., Seidler D.G. et al. (2016) Altered heparan sulfate structure in *Glce(-/-)* mice leads to increased Hedgehog signaling in endochondral bones. *Matrix Biol.* 49 82–92. doi: [10.1016/j.matbio.2015.06.004](https://doi.org/10.1016/j.matbio.2015.06.004) PMID: [26116392](https://pubmed.ncbi.nlm.nih.gov/26116392/)
  49. Orso F., Quirico L., Virga F., Penna E., Dettori D., Cimino D. et al. (2016) miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer. *Cancer Res.* 76 5151–5162. doi: [10.1158/0008-5472.CAN-15-1322](https://doi.org/10.1158/0008-5472.CAN-15-1322) PMID: [27328731](https://pubmed.ncbi.nlm.nih.gov/27328731/)
  50. Su Y., Xia W., Li J., Walz T., Humphries M.J., Vestweber D. et al. (2016) Relating conformation to function in integrin alpha5beta1. *Proc. Natl. Acad. Sci. U. S. A.* 113 E3872–81. doi: [10.1073/pnas.1605074113](https://doi.org/10.1073/pnas.1605074113) PMID: [27317747](https://pubmed.ncbi.nlm.nih.gov/27317747/)
  51. Nam E.H., Lee Y., Moon B., Lee J.W. & Kim S. (2015) Twist1 and AP-1 cooperatively upregulate integrin alpha5 expression to induce invasion and the epithelial-mesenchymal transition. *Carcinogenesis* 36 327–337. doi: [10.1093/carcin/bgv005](https://doi.org/10.1093/carcin/bgv005) PMID: [25600770](https://pubmed.ncbi.nlm.nih.gov/25600770/)
  52. Gougnard N., Maccarana M., Strate I., von Stedingk K., Malmstrom A. & Pera E.M. (2016) Musculocontractural Ehlers-Danlos syndrome and neurocristopathies: dermatan sulfate is required for *Xenopus* neural crest cells to migrate and adhere to fibronectin. *Dis. Model. Mech.* pii: dmm.024661. [Epub ahead of print]